1. What’s new in hypertension?

Efficacy and Safety Aspects of Renal Denervation in Treatment of Arterial Hypertension: A Systematic Review and Meta-analysis

D Vukadinovic

  • Compared to sham, renal denervation (RDN) was associated with
  • Reduced ambulatory and office SBP
  • No safety concerns


  1. New approaches for the prediction and prevention of ventricular arrhythmias and sudden cardiac death in ischaemic heart disease

Temporal Trends in Baseline Characteristics of Implantable Cardioverter Defibrillator Recipients for Primary Prevention of Sudden Cardiac Death- The DAIPP Program

D Frodi

  • The primary prevention Implantable Cardioverter Defibrillators (ICD) changed over time
  • Perioperative complications decreased over time
  • Increase in use of 2 or 3 medications


  1. Coronary heart disease risk prediction in asymptomatic patients: what works best?

Lost in Math: Risk Calculators

Ian M Graham

  • The new SCORE2-OP model
  • Estimates the risk of fatal and non-fatal CVD for older persons
  • SCORE2-OP is recalibrated for use in 4 European risk regions
  • Individual predictions of CVD risk and treatment benefits can be used in shared decision-making


  1. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa McDonagh

  • The guidelines recommended
  • Intravenous (IV) iron supplementation in symptomatic patients with HFrEF and HFmrEF
  • IV supplementation to alleviate HF symptoms
  • Improve quality of life
  • Reduce risk of HF hospitalization



ATTRibute-CM trial

  • Acoramidis met 30-month primary endpoint
  • Consistent treatment shows
  • Better preservation of exercise capacity and QoL
  • Reduced NT-proBNP levels in 45% of patients
  • 81% survival rate
  • Reassuring safety profile



ARREST Trial: Expedited Transfer to a Cardiac Arrest Centre for Non-ST Elevation OHCA

T Patterson

  • Transfer to the cardiac arrest centre in adult patients without ST elevation demonstrated
  • No reduction in mortality at 30 days
  • No difference in neurological outcomes


  1. Efficacy and Safety of Intravenous Iron Repletion in Patients with Heart Failure: A Systemic Review

  • FCM/FDI reduced HFH and CVD
  • No heterogeneity between FCM and FDI
  • FCM/FDI have favourable safety profile


  1. Coronary heart disease risk prediction in asymptomatic patients: what works best?

Show Me the Moves: Stress Testing

M Guazzi

  • Small changes in CRF and CV mortality over time have huge impact
  • CPET–derived data out of peak VO2 are
  • Highly prognostic in HF populations
  • Can predict worse CV outcome in general population